CLBS Caladrius Biosciences, Inc. Stock Quote

Your browser is no longer supported. Please, upgrade your browser.

publish chart | save to portfolio | create alert

Settings

CLBS [NASD]

Caladrius Biosciences, Inc.

Healthcare | Biotechnology | USA

statements

Index	-	P/E	-	EPS (ttm)	-1.81	Insider Own	3.50%	Shs Outstand	10.62M	Perf Week	16.00%
Market Cap	31.10M	Forward P/E	-	EPS next Y	-0.93	Insider Trans	0.00%	Shs Float	10.19M	Perf Month	5.73%
Income	-19.00M	PEG	-	EPS next Q	-0.39	Inst Own	17.20%	Short Float	1.67%	Perf Quarter	-11.55%
Sales	-	P/S	-	EPS this Y	-12.40%	Inst Trans	40.83%	Short Ratio	0.35	Perf Half Y	-31.42%
Book/sh	1.62	P/B	1.25	EPS next Y	40.40%	ROA	-64.70%	Target Price	-	Perf Year	-21.92%
Cash/sh	1.35	P/C	1.50	EPS next 5Y	-	ROE	-81.50%	52W Range	1.05 - 3.64	Perf YTD	-19.12%
Dividend	-	P/FCF	-	EPS past 5Y	35.50%	ROI	-	52W High	-44.23%	Beta	1.49
Dividend %	-	Quick Ratio	4.60	Sales past 5Y	-	Gross Margin	-	52W Low	93.33%	ATR	0.15
Employees	27	Current Ratio	4.60	Sales Q/Q	-	Oper. Margin	-	RSI (14)	55.35	Volatility	10.02% 7.97%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	13.80%	Profit Margin	-	Rel Volume	0.69	Prev Close	2.00
Shortable	Yes	LT Debt/Eq	0.00	Earnings	May 07 AMC	Payout	-	Avg Volume	491.06K	Price	2.03
Recom	2.20	SMA20	10.42%	SMA50	6.88%	SMA200	-12.09%	Volume	339,024	Change	1.50%

May-18-20

Downgrade

Dawson James

Buy → Neutral

Nov-20-18

Resumed

H.C. Wainwright

Buy

$18.50

Aug-23-16

Initiated

Chardan Capital Markets

Buy

$6.50

Apr-29-16

Upgrade

H.C. Wainwright

Neutral → Buy

$1.25

Jan-08-16

Downgrade

H.C. Wainwright

Buy → Neutral

Jan-07-16

Downgrade

Maxim Group

Buy → Hold

Dec-22-15

Reiterated

Maxim Group

Buy

$12 → $4

Jun-02-20 08:06AM	Caladrius Biosciences to Present on CLBS119 for COVID-19 Induced Lung Damage at the BioNJ COVID-19 Rapid Fire Research Showcase GlobeNewswire
May-28-20 01:20PM	Caladrius Biosciences Closes $4.3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules GlobeNewswire
May-26-20 08:00AM	Caladrius Biosciences Announces $4.3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules GlobeNewswire -15.87%
May-14-20 03:42PM	Caladrius Biosciences Reports Positive Full Results for CLBS16 from the ESCaPE-CMD Trial at SCAI 2020 Scientific Sessions GlobeNewswire -21.30%
May-13-20 12:16AM	Edited Transcript of CLBS earnings conference call or presentation 7-May-20 8:30pm GMT Thomson Reuters StreetEvents
May-12-20 11:15AM	Simple Market Timing Strategies That Work - May 12, 2020 Zacks +8.78%
May-07-20 04:05PM	Caladrius Biosciences Provides Corporate Update and Reports 2020 First Quarter Financial Results GlobeNewswire
May-06-20 08:30AM	Caladrius Biosciences Announces Presentation of Full Results for CLBS16 from the ESCaPE-CMD Trial at SCAI 2020 Scientific Sessions GlobeNewswire
Apr-30-20 08:30AM	Caladrius Biosciences to Host First Quarter 2020 Financial Results Conference Call on Thursday, May 7, 2020 GlobeNewswire
Apr-27-20 03:16PM	Caladrius Biosciences Closes $5.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules GlobeNewswire -5.33%
Apr-23-20 02:00PM	Caladrius Biosciences Announces $5.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules GlobeNewswire
08:55AM	Caladrius Biosciences Plans to Assess its CLBS119 Cell Therapy for Repair of COVID-19 Induced Lung Damage GlobeNewswire
Apr-22-20 08:00AM	Caladrius Biosciences to Receive $10.9 Million of Non-Dilutive Capital Through New Jersey Technology Business Tax Certificate Transfer Program GlobeNewswire
Apr-20-20 07:14AM	We're Keeping An Eye On Caladrius Biosciences's (NASDAQ:CLBS) Cash Burn Rate Simply Wall St.
Mar-26-20 10:17AM	Edited Transcript of CLBS earnings conference call or presentation 5-Mar-20 9:30pm GMT Thomson Reuters StreetEvents
Mar-17-20 07:00AM	Memgen Appoints Gregory Brown as Chief Executive Officer Newsfile -12.07%
Mar-06-20 09:22AM	The Truth About Market Timing - March 06, 2020 Zacks
Mar-05-20 04:05PM	Caladrius Biosciences Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update GlobeNewswire
02:30PM	Caladrius Biosciences, Inc. to Host Earnings Call ACCESSWIRE
Feb-27-20 08:30AM	Caladrius Biosciences to Host Fourth Quarter and Full Year 2019 Financial Results Conference Call on Thursday, March 5, 2020 at 4:30 p.m. Eastern Time GlobeNewswire -8.93%
Feb-03-20 08:30AM	Caladrius Biosciences to Participate at Upcoming February Conferences GlobeNewswire
Jan-27-20 09:17AM	The Market Timing Secrets No One Talks About - January 27, 2020 Zacks
Jan-21-20 07:35AM	Does Caladrius Biosciences, Inc. (NASDAQ:CLBS) Have A Particularly Volatile Share Price? Simply Wall St.
Jan-07-20 04:05PM	Caladrius Biosciences to Participate at Upcoming January Conferences GlobeNewswire
10:00AM	Simple Market Timing Strategies That Work - January 07, 2020 Zacks
Dec-02-19 04:05PM	Caladrius Biosciences to Participate at Upcoming December Conferences GlobeNewswire -7.14%
Nov-25-19 08:56AM	Timing the Market, Is it Possible? - November 25, 2019 Zacks
Nov-19-19 05:56PM	Edited Transcript of CLBS earnings conference call or presentation 6-Nov-19 9:30pm GMT Thomson Reuters StreetEvents
Nov-16-19 03:59PM	Caladrius Biosciences Reports Positive Results for CLBS16 from the ESCaPE-CMD Trial at American Heart Association Scientific Sessions 2019 GlobeNewswire
Nov-06-19 04:05PM	Caladrius Biosciences Reports 2019 Third Quarter and Nine Month Financial Results and Provides Corporate Update GlobeNewswire
Nov-04-19 08:44AM	When Does Market Timing Actually Work? - November 04, 2019 Zacks
Oct-31-19 08:30AM	Caladrius Biosciences to Participate at Upcoming November Conferences GlobeNewswire
Oct-30-19 08:30AM	Caladrius Biosciences to Host 2019 Third Quarter Financial Results and Business Update Conference Call on Wednesday, November 6, 2019 at 4:30 p.m. Eastern Time GlobeNewswire
Oct-23-19 11:30AM	Is Caladrius Biosciences (NASDAQ:CLBS) In A Good Position To Deliver On Growth Plans? Simply Wall St. +5.86%
Oct-14-19 11:58AM	Edited Transcript of CLBS earnings conference call or presentation 8-Aug-19 8:30pm GMT Thomson Reuters StreetEvents +8.96%
08:36AM	The Market Timing Secrets No One Talks About - October 14, 2019 Zacks
Oct-01-19 08:30AM	Caladrius Biosciences to Participate at the Upcoming October Conferences GlobeNewswire
Sep-24-19 09:04AM	The Keys to Successfully Timing the Markets - September 24, 2019 Zacks
Sep-06-19 10:15AM	CORRECTING and REPLACING -- Caladrius Biosciences to Participate at the Upcoming September Conferences GlobeNewswire
Sep-05-19 04:05PM	Caladrius Biosciences to Participate at the Upcoming September Conferences GlobeNewswire
Sep-04-19 08:58AM	The Keys to Successfully Timing the Markets - September 04, 2019 Zacks
Aug-15-19 09:57AM	The Keys to Successful Timing the Markets - August 15, 2019 Zacks
Aug-08-19 04:05PM	Caladrius Biosciences Reports 2019 Second Quarter and First Six Months Financial Results and Provides Corporate Update GlobeNewswire
Aug-07-19 08:30AM	Caladrius Biosciences and Cognate BioServices Establish Manufacturing Agreement for Phase 3 Confirmatory Pivotal Clinical Trial of CLBS14 in No-option Refractory Disabling Angina GlobeNewswire
Aug-05-19 10:55AM	Top Ranked Momentum Stocks to Buy for August 5th Zacks
Aug-01-19 08:30AM	Caladrius Biosciences to Host 2019 Second Quarter Financial Results Conference Call on Thursday, August 8, 2019 at 4:30 p.m. Eastern Time GlobeNewswire
Jul-25-19 03:04PM	If You Had Bought Caladrius Biosciences (NASDAQ:CLBS) Stock Five Years Ago, You'd Be Sitting On A 95% Loss, Today Simply Wall St.
11:27AM	Top Ranked Momentum Stocks to Buy for July 25th Zacks
Jul-15-19 08:30AM	Caladrius Biosciences Receives Advanced Therapy Medicinal Product Classification for CLBS12, its CD34+ Cell Therapy for Critical Limb Ischemia GlobeNewswire +11.79%
Jun-04-19 08:30AM	Caladrius Biosciences Completes Enrollment in Phase 2 ESCaPE-CMD Trial for Coronary Microvascular Dysfunction GlobeNewswire
May-24-19 03:53AM	Edited Transcript of CLBS earnings conference call or presentation 9-May-19 8:30pm GMT Thomson Reuters StreetEvents
May-09-19 04:05PM	Caladrius Biosciences Reports 2019 First Quarter Financial Results and Provides Corporate Update GlobeNewswire
May-07-19 08:30AM	Caladrius Biosciences to Participate at the Upcoming May Conferences GlobeNewswire
May-02-19 08:30AM	Caladrius Biosciences to Host 2019 First Quarter Financial Results Conference Call on Thursday, May 9, 2019 at 4:30 p.m. Eastern Time GlobeNewswire
Apr-25-19 02:23PM	How Does Caladrius Biosciences, Inc. (NASDAQ:CLBS) Affect Your Portfolio Volatility? Simply Wall St.
Apr-03-19 08:30AM	Caladrius Biosciences to Participate in Upcoming Conferences GlobeNewswire
Mar-14-19 04:23PM	Caladrius Biosciences Reports 2018 Fourth Quarter and Year End Financial Results ACCESSWIRE
04:20PM	Caladrius Biosciences announces Purchase Agreement with Lincoln Park Capital for up to $26 million ACCESSWIRE
Mar-13-19 04:05PM	Caladrius Biosciences to Host 2018 Fourth Quarter and Year End Financial Results Conference Call on Thursday, March 14, 2019 at 4:30 p.m. Eastern Time GlobeNewswire
Mar-11-19 02:20PM	What Kind Of Shareholder Appears On The Caladrius Biosciences, Inc.s (NASDAQ:CLBS) Shareholder Register? Simply Wall St.
08:30AM	Caladrius Biosciences to Present at the Alliance for Regenerative Medicine 7th Annual Cell & Gene Therapy Investor Day GlobeNewswire
Feb-13-19 05:26PM	Caladrius Biosciences Reports Top-Line Data for the Phase 2a Sanford Project: T-Rex Trial of CLBS03 for Recent Onset Type 1 Diabetes GlobeNewswire
Feb-05-19 08:00AM	Caladrius Biosciences to Present at Upcoming February Conferences GlobeNewswire
Jan-23-19 09:04AM	What Makes Caladrius Biosciences (CLBS) a New Buy Stock Zacks
Jan-07-19 08:00AM	Caladrius Biosciences to Participate in Upcoming January Conferences GlobeNewswire
Nov-15-18 07:25AM	Recent Analysis Shows Escalade, Caladrius Biosciences, LightInTheBox Holding Co., Vishay Intertechnology, Ceridian HCM Holding, and Avista Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Nov-09-18 08:30AM	Caladrius Biosciences to Participate in the Inv$tival Showcase in Partnership with Jefferies and the Jefferies 2018 London Healthcare Conference GlobeNewswire -13.05%
Nov-08-18 04:05PM	Caladrius Biosciences Reports 2018 Third Quarter Financial Results GlobeNewswire +6.54%
08:30AM	Caladrius Biosciences Appoints Cynthia Schwalm to Board of Directors GlobeNewswire
Nov-02-18 08:00AM	Caladrius Biosciences to Host Third Quarter 2018 Financial Results Conference Call on Thursday, November 8, 2018 at 4:30 p.m. ET GlobeNewswire
Oct-01-18 08:36AM	Caladrius Biosciences Inc (NASDAQ:CLBS): How Does It Impact Your Portfolio? Simply Wall St.
Sep-27-18 08:00AM	Caladrius Biosciences to Participate in Upcoming October Conferences GlobeNewswire
Sep-21-18 11:24AM	Caladrius Biosciences (CLBS) Shares March Higher, Can It Continue? Zacks -8.46%
Sep-12-18 09:30AM	Is Caladrius Biosciences (CLBS) Stock Outpacing Its Medical Peers This Year? Zacks
Sep-11-18 08:00AM	Danforth Advisors Names Robert Dickey IV Managing Director, Mid Atlantic Region GlobeNewswire
Aug-09-18 04:05PM	Caladrius Biosciences Reports 2018 Second Quarter and First Six Months Financial Results GlobeNewswire +7.77%
02:30PM	Caladrius Biosciences, Inc. to Host Earnings Call ACCESSWIRE
Aug-02-18 08:00AM	Caladrius Biosciences to Host Second Quarter 2018 Financial Results Conference Call on Thursday, August 9, 2018 at 4:30 p.m. ET GlobeNewswire
Jun-20-18 08:00AM	Today's Research Reports on Stocks to Watch: Sarepta Therapeutics and Caladrius Biosciences ACCESSWIRE +30.71%
Jun-19-18 08:00AM	Caladrius Receives FDA Regenerative Medicine Advanced Therapy Designation for CD34+ Cell Therapy for Treating Refractory Angina GlobeNewswire +67.34%
Jun-05-18 08:00AM	Caladrius Biosciences Sells Rights to Counter-Flow Centrifugation System to Hitachi Chemical Advanced Therapeutics Solutions GlobeNewswire
May-10-18 04:05PM	Caladrius Biosciences Reports 2018 First Quarter Financial Results GlobeNewswire
09:39AM	For Diabetes Patients, Management Solutions Are As Critical As Medications Market Exclusive
May-07-18 08:00AM	Caladrius Biosciences to Participate at the 15th International Symposium on Cardiovascular Regeneration and Repair GlobeNewswire
May-03-18 08:00AM	Caladrius Biosciences to Host First Quarter 2018 Financial Results Conference Call on Thursday, May 10, 2018 at 4:30 p.m. Eastern Time GlobeNewswire
Apr-20-18 07:20AM	Wired News - Mesoblast Announced Updated Data from Phase-3 and Phase-2b Clinical Trials of MPC-150-IM in Patients with Chronic Heart Failure ACCESSWIRE
Apr-10-18 08:00AM	Caladrius Biosciences Receives SAKIGAKE Expedited Review Designation in Japan for CLBS12 for Treating Critical Limb Ischemia GlobeNewswire -5.27%
Apr-09-18 04:00PM	Caladrius Biosciences to Participate at Upcoming April Conferences GlobeNewswire
Apr-03-18 08:00AM	Caladrius Biosciences to Present at The MicroCap Conference GlobeNewswire
Mar-22-18 04:05PM	Caladrius Biosciences Reports 2017 Fourth Quarter and Year End Financial Results GlobeNewswire
12:00PM	Caladrius Biosciences, Inc. to Host Earnings Call ACCESSWIRE
Mar-15-18 08:00AM	Caladrius Biosciences to Host Fourth Quarter and Year End 2017 Financial Results Conference Call on Thursday, March 22, 2018 at 4:30 p.m. Eastern Time GlobeNewswire
Mar-13-18 08:00AM	Caladrius Biosciences Doses First Patient with CLBS12 in Phase 2 Critical Limb Ischemia Trial in Japan GlobeNewswire
Mar-08-18 04:05PM	Caladrius Biosciences to Present at the B. Riley FBR Inaugural China Healthcare Investing & Partnering Symposium GlobeNewswire -6.28%
08:00AM	Caladrius Biosciences Reports Interim Analysis for Phase 2 T-Rex Trial of CLBS03 for Type 1 Diabetes GlobeNewswire
Mar-06-18 08:00AM	Caladrius Biosciences Acquires an Exclusive License to a Late Stage CD34+ Cell Therapy Program for the Treatment of Refractory Angina GlobeNewswire +8.95%
Feb-07-18 08:00AM	Caladrius Biosciences to Present at the 2018 BIO CEO & Investor Conference GlobeNewswire
Jan-18-18 08:00AM	Caladrius Biosciences Announces Completion of Enrollment of Phase 2 T-Rex Clinical Trial of CLBS03 for Type 1 Diabetes GlobeNewswire
Dec-08-17 12:33PM	ETFs with exposure to Caladrius Biosciences, Inc. : December 8, 2017 Capital Cube +8.19%
Dec-01-17 08:30AM	Caladrius Biosciences to Present at the 10th Annual LD Micro Main Event GlobeNewswire

Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, develops cellular therapeutic product candidates to address diseases and conditions caused by ischemia. Its product candidates include developmental treatments for cardiovascular diseases, such as CLBS12 for the treatment of critical limb ischemia; CLBS16, which is in Phase II clinical trial for the treatment of coronary microvascular dysfunction; CLBS14, a regenerative medicine advanced therapy for treating no-option refractory disabling angina. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc. was founded in 1980 and is headquartered in Basking Ridge, New Jersey.

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience